GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
K

Korea United Pharm 033270.KS · KRW

Health Care · KRX · 🇰🇷 South Korea

Compare

15,630

+0.06%

Close of 9 Nov 2026, in KRW

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in KRW, from our data supplier.

FY2025

Revenue

₩288.76bn

FY2016FY2025

Net income

₩38.31bn

FY2016FY2025

Free cash flow

₩25.99bn

FY2016FY2025

Shareholders' equity

₩454.63bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue₩288.76bn₩288.71bn₩278.94bn₩262.52bn₩221.04bn₩215.95bn₩221.31bn₩211.94bn₩197.02bn₩176.91bn
Gross profit₩160.60bn₩163.97bn₩158.98bn₩145.29bn₩122.66bn₩125.19bn₩128.59bn₩125.48bn₩111.86bn₩96.83bn
Research and development₩17.86bn₩16.21bn₩17.30bn₩15.54bn₩13.79bn₩12.27bn₩14.10bn₩12.44bn₩4.90bn₩4.01bn
Operating income₩50.11bn₩33.52bn₩55.27bn₩48.21bn₩39.56bn₩40.13bn₩35.00bn₩37.75bn₩31.72bn₩27.12bn
Net income₩38.31bn₩32.45bn₩48.26bn₩45.28bn₩28.65bn₩26.61bn₩30.92bn₩31.67bn₩27.86bn₩19.51bn
Diluted earnings per share2,576.822,182.983,246.363,045.461,927.081,790.162,079.592,130.471,874.271,312.61

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets₩519.49bn₩473.93bn₩468.86bn₩417.89bn₩380.03bn₩353.43bn₩331.24bn₩301.95bn₩265.80bn₩234.22bn
Total liabilities₩64.86bn₩67.72bn₩90.18bn₩80.03bn₩79.32bn₩76.54bn₩76.14bn₩73.47bn₩64.11bn₩56.83bn
Debt₩10.80bn₩12.81bn₩10.96bn₩7.30bn₩11.90bn₩10.21bn₩31.50bn₩28.54bn₩25.18bn₩21.22bn
Shareholders' equity₩454.63bn₩406.21bn₩378.68bn₩337.86bn₩300.71bn₩276.89bn₩255.10bn₩228.48bn₩201.68bn₩177.39bn
Shares outstanding15m15m15m15m15m15m15m15m15m15m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations₩51.14bn₩26.79bn₩49.77bn₩63.78bn₩44.09bn₩36.96bn₩38.15bn₩36.86bn₩27.68bn₩30.02bn
Capital spending−₩25.14bn−₩21.22bn−₩31.31bn−₩24.21bn−₩12.79bn−₩12.55bn−₩19.76bn−₩17.35bn−₩27.59bn−₩13.29bn
Free cash flow₩25.99bn₩5.57bn₩18.46bn₩39.57bn₩31.30bn₩24.42bn₩18.40bn₩19.52bn₩90.8m₩16.73bn
Dividends paid−₩6.62bn−₩6.14bn−₩5.88bn−₩5.49bn−₩5.20bn−₩4.89bn−₩4.89bn−₩4.44bn−₩3.70bn−₩3.39bn

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue₩77.22bn₩73.82bn₩72.65bn₩74.39bn₩70.37bn₩71.35bn₩73.18bn₩71.36bn
Gross profit₩42.85bn₩40.67bn₩40.46bn₩40.28bn₩39.54bn₩40.32bn₩38.77bn₩40.75bn
Operating income₩13.60bn₩11.26bn₩12.78bn₩12.51bn₩11.07bn₩13.78bn−₩12.33bn₩39.52bn
Net income₩37.71bn₩13.98bn₩10.93bn₩13.54bn₩1.18bn₩12.66bn₩14.40bn₩5.25bn
Diluted earnings per share2,536.32940.66735.01911.0779.40851.33968.62353.31
Cash from operations₩13.70bn₩35.58bn₩23.01bn₩11.36bn₩2.48bn₩14.29bn₩20.79bn−₩18.98bn
Capital spending−₩1.47bn−₩25.34bn−₩13.11bn−₩4.67bn−₩3.93bn−₩3.43bn−₩7.80bn−₩2.98bn
Free cash flow₩12.22bn₩10.24bn₩9.90bn₩6.69bn−₩1.45bn₩10.86bn₩12.98bn−₩21.95bn
Total assets₩570.76bn₩563.13bn₩519.49bn₩485.91bn₩478.69bn₩488.82bn₩473.93bn₩460.01bn
Debt₩10.71bn₩9.88bn₩10.80bn₩11.50bn₩11.94bn₩12.38bn₩12.81bn₩13.25bn
Shareholders' equity₩497.12bn₩459.17bn₩454.63bn₩421.86bn₩413.68bn₩412.34bn₩406.21bn₩391.83bn

Growth per year

Compound annual rate

3 years5 years10 years
Revenue3.2%6.0%5.9%
Operating income1.3%4.5%8.1%
Net income-5.4%7.6%5.8%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin56.2%56.2%56.3%56.5%
Operating margin14.5%16.7%17.1%16.7%
Net margin12.3%14.7%14.1%13.9%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings7.48.38.37.524.637.18.810.816.314.1
Price to sales1.00.91.41.33.24.61.21.62.31.6

Dividends and splits

Per share, in the currency the company pays

Paid for 25 years. Last went ex-dividend on 29 Dec 2025.

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Paid in the year1,060.00420.00400.00370.00350.00330.00330.00300.00
  • 1.02-for-1 split · 20 Jan 2014
  • 10-for-1 split · 19 Feb 2001

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.